NEW YORK--(BUSINESS WIRE)-- LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has published an independent survey of 62 gastroenterologists and infectious disease physicians on their current and expected use of DIFICID, a newly commercialized antibiotic for the treatment of Clostridium difficile-associated diarrhea (CDAD) from Optimer Pharmaceuticals, Inc. (NasdaqGM:OPTR - News).
“We believe these results communicate important insights into the launch of this new product,” said Andrew I. McDonald, Ph.D., Managing Director at LifeSci Advisors. “Awareness of DIFICID is high, at 85% of responders, and almost 20% intend to use the drug first line and 60% intend to use after FLAGYL failure. Ultimately, the survey responders indicated that they intend to treat 20% of their total CDAD patient population with DIFICID in 12 months.”
With 700,000 cases in the US alone this year, 20% times $2000 a treatment package results in $280,000,000 of sales. This is very encouraging. It will be instructive to see the latest sales figures (probably as part of their earnings report at the end of October).
In my 7 years in Healthcare field (inpatient and outpatient), I have seen maybe 5 patients who were not successfully treated with vancomycin or Flagyl. In the present day of saving money and insurance companies/Medicare, there is no way anyone would prescribe an expensive medication like this.
This will tank 50% by next earning date and smart money is getting out now
Really appreciate your input...but, please just keep delivering those meals to the right room...Mom hospitalized for the 3rd time and yes..it's c-dif related.....and yes shes Vanco-resistant...and yes,Dificid just hit the hospital formulary.....and no,it's not more expensive than Vanco....and yes,the early word from Hospital Docs is that they are pleased they have an alternative drug that's showing good results and I am gonna keep settin' those food trays in the buffer zone so you don't have to suit up to pick them up.....
The 5 you saw must have been part of the 109,000 mentioned below.
A recent survey of US hospitals by the Association for Professionals in Infection Control and Epidemiology estimated that the incidence of C difficile infections (CDI) is 13 per 1000 in-patients and that approximately 109,000 patients die annually from CDI, which is higher than previously estimated (Jarvis WR, Schlosser J, Jarvis AA, Chinn RY. National point prevalence of Clostridium difficile in US healthcare facility inpatients, 2008. Am J Infect Control 2009;37:263-70.).
Yeah, that's a biggie IMO. Surprised that it didn't cause an upsurg. perhaps tomorrow. I'm always amazed at how some trivial (to me) comment can make the entire market go nuts whereas a study like the one posted doesn't cause a ripple.
The Wall Street herd is so self-absorbed and science-challenged that it's almost the same scenario as "The Big Short".
Still, this is a fledgling company that has yet to prove what they'll do to handle the business portion of their sales/profits (when they get them).